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and interleukin (IL)-2] produced by Th1 cells drive cellular immu-
nity to fight intracellular pathogens including viruses, and remove 
cancerous cells, while Th2 cytokines (i.e., IL-4, IL-5, IL-9, IL-10, 
and IL-13) secreted by Th2 cells control humoral immunity by 
upregulating antibody production to protect against extracellu-
lar pathogens (Mosmann et al., 1986; Romagnani, 1991; Bouman 
et al., 2005; Lehrnbecher et al., 2005; Croxford and Buch, 2011). 
Immune dysfunction resulting from imbalanced regulation and 
expression of Th1 and Th2 cytokines play an important role in the 
development of NHL (Mori et al., 2001; Chiu and Weisenburger, 
2003). Single nucleotide polymorphisms (SNPs) in several Th1/
Th2 cytokine genes (i.e., IL4, IL5, IL6, IL10, IFNGR2, IL12A, IL13, 
IL7R, and TNF) have been reported to be associated with the risk 
of NHL and its major subtypes (Lan et al., 2006; Chen et al., 2011). 
It is possible that genetic variation in the Th1/Th2 cytokine genes 
may modify the relationship between HRT and NHL risk. As such, 
we analyzed data from a population-based case–control study in 
Connecticut women to test the hypothesis.
Materials and Methods
study population
The study population has been described in detail in other stud-
ies by our group (Zhang et al., 2004a; Chen et al., 2011). Briefly, 
all histologically confirmed incident cases of NHL (ICD-O, 
introduction
Female sex hormones play an important role in modulation of 
immune system function and autoimmune disease activities (Olsen 
and Kovacs, 1996; Medina et al., 2000). Non-Hodgkin lymphoma 
(NHL) is a tumor originating in the immune system (Hoover, 1992) 
and autoimmune disease is one of the few established risk factors. 
Epidemiological studies, however, provided inconsistent results 
linking hormone replacement therapy (HRT) use and risk of NHL 
with some studies (Cerhan et al., 1997; Nelson et al., 2001; Glaser 
et al., 2003; Zhang et al., 2004b) suggesting a decreased risk and 
others (Bernstein and Ross, 1992; Cerhan et al., 2002) suggesting 
an increased risk. While the mechanisms underlying the associa-
tion between HRT and NHL remain unclear, it has been suggested 
that estrogen may act as a systemic anti-inflammatory treatment 
to lower the production of, or response to, pro-inflammatory 
cytokines (Saucedo et al., 2002). These cytokines can modulate 
lymphoid development and immune function (Hofmann et al., 
2002; Keen, 2002; Gergely et al., 2004). Therefore, some of the 
inconsistent findings linking HRT and NHL risk may be explained 
by genetic variation in cytokine genes.
T-helper cells are vital to human immune responses. The 
T-helper cell response is defined by two distinct pathways involv-
ing two different subtypes of T-helper cells, T-helper 1 (Th1) cells, 
and T-helper 2 (Th2) cells. Th1 cytokines [i.e., interferon-γ (IFN-γ) 
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sample. If there was suggestive evidence, or if we had a priori 
knowledge that a given SNP was associated with risk of NHL, 
genotype analysis would include subjects who provided only buc-
cal cell samples.
Duplicate samples from 100 study subjects to 40 replicate sam-
ples from each of two blood donors were interspersed through-
out the plates used for genotype analysis. The concordance rates 
for quality control (QC) samples were between 99 and 100% for 
all assays. The genotype frequencies for three SNPs (rs231775, 
rs2243250, and rs2070874) were not consistent with Hardy–
Weinberg equilibrium (HWE) among non-Hispanic white controls 
using a chi-square test (p < 0.05) and were excluded from the final 
analysis. To increase the statistical power for the gene–environmen-
tal interaction analysis, another five SNPs (rs2069822, rs2069818, 
rs2069807, 3024509, and rs361525) with minor allele frequency less 
than 10% were also excluded from the final analysis. A total of 31 
SNPs in 17 Th1/Th2 genes: IFNG (rs1861494, rs2069705), IFNGR1 
(rs3799488), IFNGR2 (rs9808753), IFNGR2 (rs1059293), IL10RA 
(rs9610), IL12A (rs568408, rs582054), IL13 (rs20541, rs1800925, 
rs1295686), IL15 (rs10833), IL15RA (rs2296135), IL2 (rs2069762), 
IL4 (rs2243248, rs2243290, rs2243268), IL4R (rs2107356), IL5 
(rs2069812), IL6 (rs1800795, rs1800797), IL7R (rs1494555), JAK3 
(rs3008), IL10 (rs1800871, rs1800872, rs1800896, rs3024496, 
rs3024491, rs1800890), and TNF (rs1800629, rs1799724) were 
included in the final analysis.
statistical analysis
Unconditional logistic regression models were used to estimate 
the odds ratios (ORs) and 95% confidence intervals (CIs) for 
associations between HRT, and risk of NHL and its subtypes 
in different genotype strata adjusting for age, menopausal sta-
tus, and family history of hematopoietic cancers in first degree 
relatives. We conducted analyses by separate heterozygous and 
homozygous variant genotypes and found that the risks were 
similar between heterozygous and homozygous variant geno-
types. Since the numbers for homozygous variant genotypes 
in several genes were very small, the risk estimates were unsta-
ble. As such, heterozygous and homozygous variant genotypes 
were combined for all genes to increase the statistical power. 
Adjustments for other variables, such as race, education, tobacco 
use, or alcohol consumption, did not result in material change 
of the observed associations, and thus were not included in the 
final models reported here. Significance of gene–HRT interac-
tion was assessed by adding an interaction term in the logistic 
regression models. The false discovery rate (FDR) method set 
at 0.2 was used to control for multiple comparisons (Benjamini 
and Hochberg, 1995). All p values presented are two-sided and 
all analyses were performed using SAS Software, version 9.2 (SAS 
Institute, Cary, NC, USA).
results
The distributions of selected characteristics of study population 
are presented in Table 1. Compared to controls, cases were more 
likely to have family history of hematopoietic cancers (p = 0.02). 
The proportion of postmenopausal women was greater in cases 
than in controls (p = 0.01). The distributions of age, race and HRT 
between cases and controls were not significantly different.
M-9590–9642, 9690–9701, 9740–9750) diagnosed between 1996 
and 2000 in Connecticut were identified through the Yale Cancer 
Center’s Rapid Case Ascertainment Shared Resource (RCA). 
Enrollment criteria included age between 21 and 84 years, resi-
dence in Connecticut, female, alive at the time of interview, and 
without a previous diagnosis of cancer except for non-melanoma 
skin cancer. Of 832 eligible cases, 601 (72%) completed in-per-
son interviews, and 231 (28%) refused to participate in the study. 
Pathology slides (or tissue blocks) from all patients were obtained 
from the original pathology departments and reviewed by two 
independent pathologists. All cases were classified according to 
the 2001 WHO classification (Alsheikh et al., 2001).
Female population-based controls from Connecticut were 
recruited by: (1) random-digit dialing methods for those younger 
than 65 years of age; or (2) random selection from the Centers for 
Medicare and Medicaid Services records for those aged 65 years or 
older. Controls were frequency matched on age (±5 years) to cases. 
The participation rate was 69% among persons identified via the 
random-digit dialing and 47% among persons identified from the 
Centers for Medicare and Medicaid Services. Approximately 75% of 
the study subjects (76.7% of the cases and 74.6% of the controls) 
provided blood samples, and approximately 10% of the subjects 
(11.0% of the cases and 10.4% of the controls) provided buccal 
cell samples for genotyping.
data collection
The study was approved by the institutional review boards at Yale 
University, the Connecticut Department of Public Health, and the 
National Cancer Institute. Participation was voluntary and written 
informed consent was obtained from all participants. Those who 
signed consent forms were interviewed by trained study nurses at 
the subject’s home or at a convenient location using a standardized 
and structured questionnaire. Information on anthropometrics, 
demographics, family history of cancer, smoking, and alcohol con-
sumption, occupational exposure, medical conditions and medi-
cation use, and diet were collected through in-person interview. 
An open-ended question was used to ask whether the subject had 
taken any medicine at least once a day for a period of 6 months or 
longer previous to 1 year ago, which included HRT. If yes, the age 
at first and last use, and the total months of use of the medicine 
were also ascertained (Zhang et al., 2004b).
GenotypinG
Genotyping was performed at the National Cancer Institute Core 
Genotyping Facility1. All TaqMan assays (Applied Biosystems, 
Foster City, CA, USA) for this study were optimized on the ABI 
7900HT detection system with 100% concordance with sequence 
analysis of 102 individuals as listed on the SNP500 Cancer website2. 
A total of 39 SNPs in 20 Th1/Th2 immune genes were selected 
for genotyping based on the following criteria: minor allele fre-
quencies more than 5%, laboratory evidence of function, or prior 
association with human disease studies (Lan et al., 2006). Due to a 
limited amount of DNA available for subjects who provided only 
buccal cells, we first genotyped subjects who provided a blood 
1http://cgf.nci.nih.gov
2http://snp500cancer.nci.nih.gov
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Table 1 | Distributions of selected characteristics of study population.
Characteristics Cases Controls Chi-square 
   P-value
 Number (N = 518) Percentage Number (N = 597) Percentage
Age
<50 102 19.7 117 19.6 
50–59 109 21.0 109 18.3 
60–69 132 25.5 144 24.1 
70+ 175 33.8 227 38.0 0.44
RACe
White 497 95.9 559 93.6 
Others 21 4.1 38 6.4 0.09
FAmily HisTORy OF HemATOPOieTiC CANCeR
No 473 91.3 566 94.8 
Yes 45 8.7 31 5.2 0.02
meNOPAusAl sTATus
Yes 442 85.3 475 79.6 
No 76 14.7 122 20.4 0.01
HORmONe RePlACemeNT THeRAPy
No 401 77.4 452 75.7 
Yes 117 22.6 145 24.3 0.50
Compared to women without a history of HRT use, women with 
a history of HRT use had a significantly decreased risk of NHL if 
they carried IFNGR2 (rs1059293) CT/TT genotypes (OR = 0.5, 
95%CI: 0.3–0.9), IL13 (rs20541) GG genotype (OR = 0.6, 95%CI: 
0.4–0.9) and IL13 (rs1295686) CC genotype (OR = 0.6, 95%CI: 
0.4–0.8), but not among women who carried IFNGR2 CC, IL13 
AG/AA, and IL13 CT/TT genotypes (Table 2). Similar results were 
also observed for B-cell lymphoma, but not for T-cell lymphoma. 
Significant interactions were observed for IFNGR2 (rs1059293 P
for 
interaction
 = 0.024), IL13 (rs20541 P
for interaction
 = 0.005), IL13 (rs1295686 
P
for interaction
 = 0.008), and IL15RA (rs2296135 P
for interaction
 = 0.049) for 
NHL overall; IL13 (rs20541 P
for interaction
 = 0.0009), IL13 (rs1295686 
P
for interaction
 = 0.0002), and IL15RA (rs2296135 P
for interaction
 = 0.041) 
for B-cell lymphoma. After adjustment for FDR, the interactions 
for IL13 (rs20541) and IL13 (rs1295686) with NHL overall and 
B-cell lymphoma remained statistically significant.
After stratified by common B-cell lymphoma subtypes, sig-
nificant interactions were observed for diffuse large B-cell lym-
phoma and follicular lymphoma (Table 3). Compared to women 
without a history of HRT use, women with a history of HRT use 
experienced a significantly decreased risk of diffuse large B-cell 
lymphoma if they carried IFNGR2 (rs1059293) CT/TT geno-
types (OR = 0.3, 95%CI: 0.2–0.8), IL13 (rs1295686) CC genotype 
(OR = 0.5, 95%CI: 0.3–0.9), or IL15RA (rs2296135) CT/TT geno-
types (OR = 0.5, 95%CI: 0.3–0.9). Compared to women without a 
history of HRT use, women with a history of HRT use also experi-
enced a significantly decreased risk of follicular lymphoma if they 
carried IL13 (rs20541) GG genotype (OR = 0.4, 95%CI: 0.2–0.9) 
or IL13 (rs1295686) CC genotype (OR = 0.4, 95%CI: 0.2–0.9) and 
a significantly increased risk if they carried IL13 (rs20541) AG/AA 
genotypes (OR = 2.7, 95%CI: 1.2–5.8) or IL13 (rs1295686) CT/TT 
genotypes (OR = 2.6, 95%CI: 1.2–5.5). The interactions between 
HRT and IL13 (rs20541 P
for interaction
 = 0.0003) and IL13 (rs1295686 
P
for interaction
 = 0.0005) in follicular lymphoma remained statisti-
cally significant after adjustment for FDR. Although increased or 
decreased risks were observed for several other cytokine polymor-
phisms, but none of them were statistically significant (Table A1 
in Appendix).
discussion
To our knowledge, this is the first comprehensive analysis of inter-
action between HRT, genetic polymorphisms in Th1/Th2 pathway 
genes, and the risk of NHL and its subtypes. Significant interactions 
were observed for IFNGR2 (rs1059293), IL13 (rs20541, rs1295686), 
and IL15RA (rs2296135) for NHL overall and/or B-cell NHL subtypes.
The study suggested that IL13 polymorphisms modify the asso-
ciation between HRT use and risk of B-cell lymphoma, particularly 
for follicular lymphoma. The IL13 gene encodes the IL-13 cytokine 
which exerts anti-apoptotic functions and is linked to leukemogen-
esis (Waldele et al., 2004). In vitro study also suggested that IL-13 
was a weak inducer and an amplifier of IL6 expression in vascular 
endothelial cells (Sironi et al., 1994). Estrogen has been shown to 
downregulate IL6 gene expression by endocrinological feedback 
mechanisms (Dijsselbloem et al., 2004). Studies have shown that 
higher serum levels of IL-6 were associated with an increased risk 
of B-cell lymphoma (Preti et al., 1997). It is biologically plausible 
that IL-6 expression may play an important role in our observed 
interaction between IL13 polymorphisms and HRT on the risk of 
B-cell lymphoma. Although it is currently unclear whether the two 
IL13 polymorphisms (rs20541 and rs1295686) causes over expres-
sion or enhanced function of IL-13, rs20541 has been linked to the 
risk of NHL (Wang et al., 2009).
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Table 3 | Associations between Th1/Th2 cytokine polymorphisms, hormone replacement therapy, and risk of common B-cell lymphoma subtypes1.
 DlBCl Fl
 Hormone replacement therapy Hormone replacement therapy
sNPs No yes No yes
 Cases OR2 Cases OR2(95%Ci) Cases OR2 Cases OR2(95%Ci)
IFNGR2_03 (rs1059293) 
CC 47 1.0 16 1.0(0.5–1.9) 34 1.0 12 1.1(0.5–2.3)
CT or TT 51 1.0 9 0.3(0.2–0.8) 36 1.0 11 0.7(0.3–1.5)
Pfor interaction   0.116    0.505
IL13_01(rs20541) 
GG 72 1.0 17 0.5(0.3–1.0) 54 1.0 10 0.4(0.2–0.9)
AG or AA 43 1.0 14 1.1(0.5–2.2) 24 1.0 16 2.7(1.2–5.8)
Pfor interaction   0.042    0.0003
IL13_06(rs1295686) 
CC 70 1.0 16 0.5(0.3–0.9) 53 1.0 10 0.4(0.2–0.9)
CT or TT 46 1.0 15 1.2(0.6–2.4) 26 1.0 16 2.6(1.2–5.5)
Pfor interaction   0.023    0.0005
IL15RA_02(rs2296135) 
CC 25 1.0 11 1.4(0.6–3.1) 16 1.0 8 1.6(0.6–4.4)
CT or TT 91 1.0 20 0.5(0.3–0.9) 62 1.0 17 0.7(0.4–1.3)
Pfor interaction   0.068     0.119
1DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma.
2Adjusted for age, race, menopausal status, and family history.
Table 2 | Associations between Th1/Th2 cytokine polymorphisms, hormone replacement therapy, and risk of non-Hodgkin lymphoma.
 Overall B-cell lymphoma
 Hormone replacement therapy Hormone replacement therapy
sNPs No yes No yes
 Controls Cases OR1(95%Ci) Controls Cases OR1(95%Ci) Cases OR1(95%Ci) Cases OR1(95%Ci)
IFNGR2_03 (rs1059293)
CC 175 136 1.0 55 54 1.1(0.8–1.9) 105 1.0 42 1.2(0.8–2.0)
CT or TT 125 160 1.0 47 36 0.5(0.3–0.9) 128 1.0 31 0.5(0.3–0.9)
Pfor interaction    0.024        0.052
IL13_01(rs20541)
GG 249 229 1.0 98 61 0.6(0.4–0.9) 183 1.0 47 0.6(0.4–0.9)
AG or AA 161 127 1.0 34 45 1.4(0.8–2.4) 97 1.0 41 1.7(1.0–2.9)
Pfor interaction      0.005       0.0009
IL13_06(rs1295686)
CC 227 216 1.0 94 56 0.6(0.4–0.8) 174 1.0 44 0.5(0.4–0.8)
CT or TT 175 135 1.0 37 51 1.6(1.0–2.6) 104 1.0 45 1.8(1.1–3.1)
Pfor interaction      0.008        0.0002
IL15RA_02(rs2296135)
GG 119 80 1.0 32 33 1.3(0.7–2.4) 64 1.0 29 1.5(0.8–2.8)
GT or TT 283 269 1.0 97 73 0.7(0.5–1.0) 213 1.0 59 0.7(0.5–1.1)
Pfor interaction      0.049        0.041
1Adjusted for age, race, menopausal status, and family history.
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Several strengths are included in our study. First, it is a pop-
ulation-based case–control study with histologically confirmed 
incident NHL cases which minimized potential disease misclas-
sification. Second, this study used a rapid case identification system 
to identify all eligible NHL cases eliminated survival bias given 
the aggressive nature of NHL. Eligible cases were identified within 
1 month after their diagnosis through the RCA. And finally, this 
study, for the first time, reported the effect modification of Th1/
Th2 genes on the association between HRT and NHL.
While our study included more than 1,000 study subjects, the 
statistical power is limited when investigating the relationship by 
NHL subtypes. Given the number of SNPs investigated in the study, 
chance cannot be ruled out for some of the significant findings. 
However, several significant findings remained after adjusted for 
multiple comparisons using the FDR approach.
In summary, our study provided the first suggestive evidence 
that common genetic variations in the Th1/Th2 pathway genes 
may modify the association between HRT and risk of NHL. The 
observed results could not only advance our understanding of the 
relationship between HRT use and risk of NHL but also have a 
potential impact on future clinical practices using HRT. Further 
larger population-based studies or pooled analyses with greater 
power are needed to replicate the results.
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Our study also suggested IFNGR2 polymorphism (rs1059293) 
modified the association between HRT and NHL. The gene 
IFNGR2 encodes the non-ligand-binding beta chain of the IFN-γ 
located on chromosome 21 (Mogensen et al., 1999). Initiation 
of the IFN-γ signal transduction cascade, serves to directly 
inhibit viral replication and serves to stimulate and modulate 
the immune system. A recent study suggested that HRT could 
improve postmenopausal women’s immune system by induc-
ing a significant decrease in the production of IL-10 and IFN-γ 
(Deguchi et al., 2001). Effect modification was observed for 
NHL suggesting the IFN-γ transduction pathway could play a 
role in the relationship between HRT and risk of NHL. Further 
knowledge of the functional impact of IFNGR2 polymorphism 
(rs1059293) on IFNGR2 gene is needed to help elucidate its role 
between HRT and NHL.
Potential effect modification by IL15RA (rs2296135) polymor-
phism was observed. The IL15RA gene encodes the alpha chain 
of the IL-15 receptor which is expressed in a variety of immune 
and non-immune cell types from different tissues and generates 
multiple splicing events of functional importance (Bouchaud et al., 
2008; Diniz et al., 2010). IL-15 and IL-2 receptors share the beta and 
gamma(c) subunits with private alpha chains, which presumably 
ensure the binding of the appropriate cytokine and the specific-
ity of the immune response (Vamosi et al., 2004). IL-15 and IL-2 
can activate similar janus kinase/signal transducer and activator 
of transcription (JAK/STAT)-dependent signaling pathway at the 
presence of both beta and gamma(c) subunits, suggesting a sig-
nificant overlap between the functions of IL-2 and IL-5 (Lin et al., 
1995). Recent study demonstrated that both IL-2 and IL-5 alpha 
subunits co-expressed in a supramolecular receptor cluster in lipid 
rafts of the T cells (Vamosi et al., 2004). HRT has been found to 
reduce IL-2 production (Stopinska-Gluszak et al., 2006) suggesting 
that IL-2 cytokine network plays a role in the association between 
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